98%InjectablePolypeptideHormonesTerlipressinAcetateCAS14636-12-5TerlipressinForNorepinephrine-resistantSepticShock&AggregationQuickDetails:TerlipressinAcetateCasNo.:14636-12-5EINECS:238-680-8MolecularFormula:C52H74N16O15S2M.S.:TerlipressinAcetateCAS14636-12-5PolypeptideHormonesPowderForNorepinephrine-resistantMolecularWeight:1227.37Purity(HPLC):98.0%min.Appearance:WhitepowderSingleImpurity(HPLC):1.0%maxAminoAcidComposition:&plu***n;10%oftheoreticalPeptideContent(N%):>=80.0%WaterContent(KarlFischer):>=10.0%SpecificRotation(20/D):-95.0~-105.0°(c=11%HAc)AcetateContent(HPIC):<=15.0%MS(ESI):C***istentMassBalance:95.0~105.0%Grade:PharmaceuticalGradeStorage:Closed,below2~8℃preservationUsage:Norepinephrine-resistantsepticshock,bleedingesophagealvarices,andforthecomplicati***ofcirrhosisoftheliver(esophagealandgastricvaricealbleeding,ascites,liverandkidneysyndrome)hasimportantsignificanceforthetreatmentofpatientsDescription:Terlipressin(tradenamesTeripressbyNewMediconPharmaandGlypressinbyFerringPharmaceuticals)isananalogueofvasopressinusedasavasoactivedruginthemanagementofhypotension.Ithasbeenfoundtobeeffectivewhennorepinephrinedoesnothelp.Indicati***foruseincludenorepinephrine-resistantsepticshockandhepatorenalsyndrome.Inaddition,itisusedtotreatbleedingesophagealvarices.Betweenthepatientswithcirrhosisoftheliverintotheportalcirculationofeachveinandvenouscongestioncanoccurinvascularanastomosis,portalveinpressurerisephenomenon.Themostfrequentlyappearedintheazygosveinanastomosiswithloweresophagealvarices,instanttube.Application:Thisproductispressurizedprodrughormone,vasopressinglycylininjectionintothebloodafterenzymatichydrolysisinthemoleculeisproducedacontinuouslowlevel.Theportalvenouspressureitgeneratesthedesiredeffect,butthechangesofarterialbloodpressurethantheuseofvasopressinaftermuch***aller,andthebloodofafewdonotincreasethefibrinolytic.Pushonceitsrolecanbemaintainedforabout4~6h.Intr***enousinjection,2mg,every4~6hagain,untilthecontrol,useatmost24h.Itisnotforchildren.)